GU Cancers 2026 | Managing enfortumab vedotin neuropathy in curative bladder cancer
Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, comments on the importance of identifying toxicity, specifically neuropathy, associated with enfortumab vedotin in the perioperative and neoadjuvant settings for bladder cancer. Early intervention will minimize long-term side effects, particularly in patients who may be potentially cured of their disease. Clinicians will need to balance the benefits of therapy with the risk of lifelong neuropathy. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So as Enfortumab vedotin is growing earlier and earlier in the perioperative setting and the neoadjuvant setting, it’s very important to identify toxicity and specifically neuropathy because of Enfortumab vedotin in order to be able to actually intervene and keep patients with the least amount of toxicity and the longer duration of therapy to get the most benefit...
So as Enfortumab vedotin is growing earlier and earlier in the perioperative setting and the neoadjuvant setting, it’s very important to identify toxicity and specifically neuropathy because of Enfortumab vedotin in order to be able to actually intervene and keep patients with the least amount of toxicity and the longer duration of therapy to get the most benefit. And of course we want these people that are going to be potentially cured from this disease not to have to live with neuropathy lifelong.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
